Scott Bratman

Biomarkers In Oral CANcer (BIO-CAN)

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE)

Leveraging ctDNA to Diagnose and Monitor Relapsed and Newly Diagnosed Lymphoma (READILY)

Non-Invasive Monitoring of Liver Cancer Recurrence Following Surgery and/or Transplant Using Circulating Tumour DNA Sequencing (ctDNA in HCC)

Canadian Head And Neck cancer GEnomic (CHANGE) Collaborative

Understanding the molecular underpinnings of high recurrence rates in oral squamous cell carcinoma to improve survival and quality of life for patients

Scott Bratman

Projects

Biomarkers In Oral CANcer (BIO-CAN)

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE)

Leveraging ctDNA to Diagnose and Monitor Relapsed and Newly Diagnosed Lymphoma (READILY)

Non-Invasive Monitoring of Liver Cancer Recurrence Following Surgery and/or Transplant Using Circulating Tumour DNA Sequencing (ctDNA in HCC)

Canadian Head And Neck cancer GEnomic (CHANGE) Collaborative

Patient-focused evAluatioN Of dispaRities AMong pArticipants enrolled into PRecision Oncology studies (PANORAMA-PRO)

Princess Margaret Cancer Consortium

Supported By